How should low‑normal total testosterone be evaluated and managed?

Evaluation and Management of Low-Normal Total Testosterone

A low-normal total testosterone level (typically 300-350 ng/dL) requires both confirmatory testing and symptom assessment before any treatment decision—testosterone therapy should only be initiated if the patient has both persistently low testosterone on repeat early morning testing AND specific hypogonadal symptoms, not based on the laboratory value alone. 1

Diagnostic Approach

Initial Confirmation

• Obtain a second early morning (7-11 AM) fasting total testosterone measurement using the same laboratory and methodology 1
• The diagnosis of testosterone deficiency requires both biochemical confirmation AND clinical symptoms/signs—never treat based on lab values alone 1
• If the repeat value remains in the low-normal range (300-350 ng/dL), measure free testosterone or calculated free testosterone, as this may be more clinically relevant than total testosterone in borderline cases 2, 3

Critical pitfall: Men with normal total testosterone but low free testosterone (due to elevated SHBG) are more likely to have genuine hypogonadal symptoms than men with low total testosterone but normal free testosterone (typically obese men with low SHBG) 2. This is why free testosterone assessment is essential in the low-normal range.

Symptom Assessment

Specifically inquire about these high-specificity symptoms 1, 4:

• Reduced libido and sexual activity
• Decreased spontaneous erections
• Loss of body/pubic hair, reduced shaving frequency
• Hot flushes
• Reduced muscle bulk and strength
• Low trauma fractures or known low bone density
• Infertility or very small testes

Lower-specificity symptoms (fatigue, poor concentration, depression, sleep disturbance) are common but less diagnostic 4. Do not rely on questionnaires—they lack adequate specificity 1.

Physical Examination

Document these specific findings 1:

• Body mass index and waist circumference
• Virilization status: body hair distribution in androgen-dependent areas
• Gynecomastia
• Testicular size, consistency, and presence of masses
• Varicocele presence

Essential Laboratory Workup

Measure LH and FSH levels to distinguish primary from secondary hypogonadism 1:

• Low or low-normal LH with low testosterone = secondary (central) hypogonadism → measure prolactin 1
• Elevated LH with low testosterone = primary (testicular) hypogonadism → consider karyotype if Klinefelter syndrome suspected 4

If prolactin is elevated, pursue endocrine evaluation including pituitary imaging 1.

Management Decision Algorithm

If Testosterone Remains Low-Normal (300-350 ng/dL) on Repeat Testing:

1. Measure free testosterone 2, 3:

• If free testosterone is low (<120 pg/mL in men 19-39 years; <66 pg/mL in older men) 3 AND patient has specific hypogonadal symptoms → treat as testosterone deficiency
• If free testosterone is normal despite low-normal total testosterone → do not treat with testosterone therapy; address underlying conditions (obesity, metabolic syndrome) 2

2. Address reversible causes FIRST 4:

• Acute or chronic illness
• Medications: opioids, high-dose glucocorticoids
• Obesity and metabolic syndrome
• Excessive exercise or eating disorders
• Sleep apnea

3. Consider high-risk conditions that warrant testosterone measurement even without symptoms 1:

• Unexplained anemia
• Bone density loss
• Diabetes
• HIV/AIDS
• Chronic narcotic use
• History of chemotherapy or testicular radiation
• Pituitary dysfunction
• Chronic corticosteroid use

Treatment Initiation Criteria

Initiate testosterone therapy ONLY if ALL of the following are met 1, 5:

1. Two early morning total testosterone levels <300 ng/dL OR free testosterone <120 pg/mL (young men) or <66 pg/mL (older men) 1, 3
2. Presence of specific hypogonadal symptoms (particularly sexual dysfunction, reduced muscle mass, or bone loss) 1
3. No contraindications present 6, 7

For men with sexual dysfunction specifically: The 2020 American College of Physicians guideline recommends discussing potential testosterone therapy, but emphasizes reevaluation at 12 months and discontinuation if no improvement in sexual function 8. This represents a more conservative approach than other guidelines.

If Treatment Is NOT Indicated

For asymptomatic men or those with only nonspecific symptoms (fatigue, mild mood changes) and low-normal testosterone 8:

• Do not initiate testosterone therapy for energy, vitality, physical function, or cognition alone
• Focus on lifestyle modification: weight loss through caloric restriction and exercise can increase testosterone by 1-2 nmol/L 9
• Address obesity, metabolic syndrome, and diabetes aggressively
• Recheck testosterone in 6-12 months if clinical suspicion remains high

Special Consideration: Secondary Hypogonadism with Fertility Concerns

If LH is low/normal and the patient desires fertility 1, 9:

• Do not use testosterone therapy (suppresses spermatogenesis)
• Consider gonadotropin therapy (hCG ± FSH) or selective estrogen receptor modulators
• Refer to reproductive endocrinology or urology

Monitoring If Treatment Is Initiated

At 3 months 9, 7:

• Total testosterone level (target mid-normal range: 450-600 ng/dL)
• Symptom response assessment
• Hematocrit (discontinue if >54%)
• PSA and digital rectal exam

Every 6-12 months thereafter 9, 7:

• Same parameters as 3-month visit
• Bone density if indicated
• Metabolic parameters

Discontinue therapy if no symptom improvement by 12 months 8.

Key Clinical Pearls

The 2018 AUA guideline 1 and 2025 EAU guideline 9 represent the most current authoritative sources and emphasize that up to 25% of men receiving testosterone therapy do not meet diagnostic criteria—this overtreatment stems from treating laboratory values rather than clinical syndromes. The low-normal range is particularly prone to this error.

The most common mistake: Treating men with low-normal total testosterone who have normal free testosterone (typically obese men with low SHBG). These men do not have true testosterone deficiency and will not benefit from testosterone therapy 2. Address their obesity and metabolic dysfunction instead.